Le Lézard
Classified in: Health, Science and technology
Subject: SVY

Viral Vector and Plasmid DNA Manufacturing Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027


NEW YORK, May 21, 2019 /PRNewswire/ --

Viral Vector & Plasmid DNA Manufacturing Market: Overview
This report analyzes the current and future scenario of the global viral vector & plasmid DNA manufacturing market for the period 2019 to 2027. Increase in prevalence and incidence rates of cancer, genetic disorders and infectious diseases, high unmet needs in patients with rare disorders, and raised acceptance for comparatively newer treatment options in developing countries are likely to be major drivers of the global viral vector & plasmid DNA manufacturing market during the forecast period.



Read the full report: https://www.reportlinker.com/p05775478/?utm_source=PRN



The viral vector & plasmid DNA manufacturing market report comprises an elaborate executive summary, including a snapshot that provides information on various segments of the market.It also provides information and data analysis of the global market with respect to segments based on type, application, disease, end-user, and region.

A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section.Additionally, the section comprises competitive matrix and profiles of key market players, along with business overview, to project the competitive landscape of the market.

The section also provides market attractiveness analysis based on region and market share analysis in terms of key players, thereby presenting a thorough analysis of the overall competitive scenario in the viral vector & plasmid DNA manufacturing market.

Viral Vector & Plasmid DNA Manufacturing Market: Key Segments
Based on type, the global viral vector & plasmid DNA manufacturing market has been segmented into lentivirus, adenovirus, adeno-Associated Virus (AAV), plasmid DNA, and others.In terms of application, the global viral vector & plasmid DNA manufacturing market has been divided into gene therapy, vaccinology, and others.

Based on disease, the market has been segregated into genetic disorders, cancer, infectious disease, and others.In terms of end-user, the market has been bifurcated into biotech companies and research institutes.

The market size and forecast for each of these segments have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year.

Viral Vector & Plasmid DNA Manufacturing Market: Regional Outlook
In terms of region, the global viral vector & plasmid DNA manufacturing market has been segmented into five major regions: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). Market size and forecast for each of these regions and the mentioned countries have been provided for the period 2019 to 2027, along with their respective CAGR for the forecast period 2017 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report
The report also profiles major players operating in the global viral vector & plasmid DNA manufacturing market based on various attributes, such as company overview, financial overview, product portfolio, business strategies, and recent developments. The players covered in the report include CobraBiologics, Novasep Inc., Cell and Gene Therapy Catapult, Kaneka Eurogentec S.A., FUJIFILM Diosynth Biotechnologies Inc., Spark Therapeutics, Inc. Merck KGaA, uniQure N.V., and Lonza. The global viral vector & plasmid DNA manufacturing market has been segmented as below:

Viral Vector & Plasmid DNA Manufacturing Market, by Type
Lentivirus
Adenovirus
Adeno-Associated Virus (AAV)
Plasmid DNA
Others

Viral Vector & Plasmid DNA Manufacturing Market, by Application
Gene Therapy
Vaccinology
Others

Viral Vector & Plasmid DNA Manufacturing Market, by Disease
Genetic Disorders
Cancer
Infectious Disease
Others
Viral Vector & Plasmid DNA Manufacturing Market , by End-user
Biotech Companies
Research Institutes

Viral Vector & Plasmid DNA Manufacturing Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
GCC Countries
Rest of Middle East & Africa

Read the full report: https://www.reportlinker.com/p05775478/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 06:35
HEXO Corp ("HEXO" or the "Company") plans to release its complete financial results for the quarter ended April 30, 2020, before market hours on Thursday, June 11th, 2020, as well as host a webcast for investors beginning at 8:30 a.m. EST. Webcast...

at 06:15
In honor of Pride Month, a month dedicated to recognizing the LGBTQ community, Shady Grove Fertility (SGF) is hosting two events to spread awareness about the multiple family building options available to the LGBTQ community. Tomer Singer, M.D., who...

at 06:05
Atlas Venture, a leading early stage venture capital firm investing in groundbreaking biotech innovation, today announced the closing of its twelfth fund, raising $400 million in a highly oversubscribed fundraise. With the closing of Fund XII,...

at 06:05
Insulet Corporation (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced it has resumed its pivotal study of Omnipod, Powered by Horizontm, the Company's...

at 06:00
U.S. Renal Care (USRC), a leading provider of dialysis services for patients living with kidney disease, announced today that it has named 25?year industry veteran, Mark Caputo, as Chief Executive Officer, following a national search of top tier...

at 06:00
Perception Health, a leading provider of data analytics and predictive intelligence for the healthcare market, announced today the addition of several executives to the management team....



News published on 21 may 2019 at 20:02 and distributed by: